Abstract
High-dose chemotherapy (HDT) plus autologous stem cell transplantation (ASCT) is the standard of care for chemosensitive relapsed and refractory diffuse large B-cell lymphoma (rel/ref DLBCL). Interim restaging with functional imaging by positron emission tomography using 18F-deoxyglucose (FDG-PET) has not been established after salvage chemotherapy (ST) and before HDT-ASCT by modern criteria. Herein, we evaluated 129 patients with rel/ref DLBCL proceeding to HDT-ASCT, with ST response assessment by FDG-PET according to the contemporary Deauville 5-point scale. At 3 years, patients achieving a Deauville response of 1 to 3 to ST experienced superior progression-free survival (PFS) and overall survival (OS) rates of 77% and 86%, respectively, compared with patients achieving Deauville 4 (49% and 54%, respectively) (P < .001). No other pre-HDT-ASCT risk factors significantly impacted PFS or OS. Despite achieving remission to ST, patients with Deauville 4 should be the focus of risk-adapted investigational therapies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2579-2581 |
| Number of pages | 3 |
| Journal | Blood |
| Volume | 125 |
| Issue number | 16 |
| DOIs | |
| State | Published - Apr 16 2015 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology
Cite this
Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. / Sauter, Craig S.; Matasar, Matthew J.; Meikle, Jessica; Schoder, Heiko; Ulaner, Gary A.; Migliacci, Jocelyn C.; Hilden, Patrick; Devlin, Sean M.; Zelenetz, Andrew D.; Moskowitz, Craig.
In: Blood, Vol. 125, No. 16, 16.04.2015, p. 2579-2581.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma
AU - Sauter, Craig S.
AU - Matasar, Matthew J.
AU - Meikle, Jessica
AU - Schoder, Heiko
AU - Ulaner, Gary A.
AU - Migliacci, Jocelyn C.
AU - Hilden, Patrick
AU - Devlin, Sean M.
AU - Zelenetz, Andrew D.
AU - Moskowitz, Craig
PY - 2015/4/16
Y1 - 2015/4/16
N2 - High-dose chemotherapy (HDT) plus autologous stem cell transplantation (ASCT) is the standard of care for chemosensitive relapsed and refractory diffuse large B-cell lymphoma (rel/ref DLBCL). Interim restaging with functional imaging by positron emission tomography using 18F-deoxyglucose (FDG-PET) has not been established after salvage chemotherapy (ST) and before HDT-ASCT by modern criteria. Herein, we evaluated 129 patients with rel/ref DLBCL proceeding to HDT-ASCT, with ST response assessment by FDG-PET according to the contemporary Deauville 5-point scale. At 3 years, patients achieving a Deauville response of 1 to 3 to ST experienced superior progression-free survival (PFS) and overall survival (OS) rates of 77% and 86%, respectively, compared with patients achieving Deauville 4 (49% and 54%, respectively) (P < .001). No other pre-HDT-ASCT risk factors significantly impacted PFS or OS. Despite achieving remission to ST, patients with Deauville 4 should be the focus of risk-adapted investigational therapies.
AB - High-dose chemotherapy (HDT) plus autologous stem cell transplantation (ASCT) is the standard of care for chemosensitive relapsed and refractory diffuse large B-cell lymphoma (rel/ref DLBCL). Interim restaging with functional imaging by positron emission tomography using 18F-deoxyglucose (FDG-PET) has not been established after salvage chemotherapy (ST) and before HDT-ASCT by modern criteria. Herein, we evaluated 129 patients with rel/ref DLBCL proceeding to HDT-ASCT, with ST response assessment by FDG-PET according to the contemporary Deauville 5-point scale. At 3 years, patients achieving a Deauville response of 1 to 3 to ST experienced superior progression-free survival (PFS) and overall survival (OS) rates of 77% and 86%, respectively, compared with patients achieving Deauville 4 (49% and 54%, respectively) (P < .001). No other pre-HDT-ASCT risk factors significantly impacted PFS or OS. Despite achieving remission to ST, patients with Deauville 4 should be the focus of risk-adapted investigational therapies.
UR - http://www.scopus.com/inward/record.url?scp=84927751342&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84927751342&partnerID=8YFLogxK
U2 - 10.1182/blood-2014-10-606939
DO - 10.1182/blood-2014-10-606939
M3 - Article
C2 - 25758829
AN - SCOPUS:84927751342
VL - 125
SP - 2579
EP - 2581
JO - Blood
JF - Blood
SN - 0006-4971
IS - 16
ER -